Aveir DR i2i Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 464 participants.

Also called NCT05252702

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 464 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05252702
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, Canada, Czechia, France, Hong Kong SAR China, Italy, Japan, Netherlands, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05252702. Allocation not applicable; no masking; primary purpose treatment. Start 2022-02-02 (actual); primary completion 2023-08-02 (actual). Results posted on 2024-11-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Aveir DR i2i Study
Condition
Cardiac Pacemaker, Artificial
Condition
Cardiac Rhythm Disorder
Condition
Bradycardia
Intervention (Device)
Aveir DR Leadless Pacemaker System
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct05252702
Content hash
e517d6fc9031d0772ad042f95add4b0f89b2e43e66b3c5637308220b2dc79273